Novartis AG
NVSEF
$157.90
$6.484.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.52% | -0.91% | 1.39% | 8.47% | 12.32% |
| Total Other Revenue | -30.56% | 6.20% | 29.38% | 28.65% | 117.22% |
| Total Revenue | 0.78% | -0.70% | 2.23% | 9.00% | 15.26% |
| Cost of Revenue | 10.72% | 6.54% | 6.94% | 9.31% | 4.70% |
| Gross Profit | -2.09% | -2.95% | 0.70% | 8.91% | 18.71% |
| SG&A Expenses | -6.13% | 2.58% | -1.80% | 5.42% | 11.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -61.98% | -84.15% | 121.35% | -91.00% | 30.47% |
| Total Operating Expenses | -0.51% | 5.45% | 21.24% | 2.46% | 10.55% |
| Operating Income | 3.29% | -12.37% | -27.35% | 26.17% | 25.75% |
| Income Before Tax | -5.78% | -12.89% | -2.04% | 23.96% | 17.96% |
| Income Tax Expenses | 99.61% | -14.41% | 75.05% | 33.00% | -14.79% |
| Earnings from Continuing Operations | -19.06% | -12.55% | -14.75% | 23.39% | 23.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -58.82% | -- | 350.00% | -150.00% | -- |
| Net Income | -19.23% | -12.48% | -14.51% | 23.17% | 24.49% |
| EBIT | 3.29% | -12.37% | -27.35% | 26.17% | 25.75% |
| EBITDA | 3.21% | -9.52% | -22.64% | 22.14% | 21.09% |
| EPS Basic | -17.40% | -9.77% | -11.20% | 28.68% | 29.92% |
| Normalized Basic EPS | 3.06% | -12.30% | -31.26% | 31.87% | 28.82% |
| EPS Diluted | -16.99% | -9.34% | -11.57% | 28.66% | 29.56% |
| Normalized Diluted EPS | 3.21% | -12.13% | -31.25% | 31.88% | 28.84% |
| Average Basic Shares Outstanding | -2.21% | -3.00% | -3.72% | -4.27% | -4.18% |
| Average Diluted Shares Outstanding | -2.35% | -3.18% | -3.74% | -4.29% | -4.20% |
| Dividend Per Share | -- | -- | 20.81% | -- | -- |
| Payout Ratio | 0.43% | 0.33% | -- | -- | -0.17% |